ArticleCancers2021

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry.

Lina María Serna-Higuita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.